** Shares of transdermal pharma products maker Nutriband
rise ~28% to $6.67
** Brokerage Noble Capital starts coverage on NTRB with "outperform" rating and sets PT at $13
** PT represents a 148% upside to the stock's last
** NTRB is developing Aversa, a proprietary technology that makes transdermal patches safer by preventing abuse and misuse of potent opioids like fentanyl
** Brokerage says NTRB's tech has "abuse-deterrent" features that differentiate it from other transdermal patches on the market
** Also notes NTRB's partnership to add the Aversa technology to Kindeva's transdermal fentanyl patch could be a highly effective means to stop misuse
** NTRB shares doubled in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.